APELLIS PHARMACEUTICALS INC. - COMMON STOCK

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Sep 2023 16:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

30 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Apellis Announces Corporate Restructuring to Drive Growth of SYFOVRE® (pegcetacoplan injection) and EMPAVELI® (pegcetacoplan), Positioning Company for Long-Term Success

29 Aug 2023 06:58:00 By Nasdaq GlobeNewswire

Apellis Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE® (pegcetacoplan injection)

22 Aug 2023 16:43:29 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Aug 2023 16:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results

31 Jul 2023 07:00:00 By Nasdaq GlobeNewswire

SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 30 Months in Patients with Geographic Atrophy (GA)

30 Jul 2023 13:00:40 By Nasdaq GlobeNewswire

Apellis Provides Update on Review of Rare Safety Events with SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy

29 Jul 2023 14:52:12 By Nasdaq GlobeNewswire

Apellis Announces Seven Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting

10 Jul 2023 07:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Jul 2023 16:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

07 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Jun 2023 16:05:00 By Nasdaq GlobeNewswire

Apellis Reports Top-Line Results from Phase 2 MERIDIAN Study in ALS

25 May 2023 07:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 May 2023 16:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Reports First Quarter 2023 Financial Results

04 May 2023 16:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at the Bank of America Securities 2023 Healthcare Conference

03 May 2023 07:00:01 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host Conference Call on May 4, 2023, to Discuss First Quarter 2023 Financial Results

27 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

Apellis Presents Phase 3 Functional Analyses of SYFOVRE™ (pegcetacoplan injection) for Geographic Atrophy

23 Apr 2023 18:05:00 By Nasdaq GlobeNewswire

Apellis Announces Validation of Four Marketing Applications for Pegcetacoplan for Geographic Atrophy

21 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

Apellis Partners with Acclaimed Actor Henry Winkler to Raise Awareness of Geographic Atrophy (GA) for the GA Won’t Wait™ Campaign

17 Apr 2023 07:00:00 By Nasdaq GlobeNewswire